Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adiphenine SCHEMBL33478 | 0.98 | CYP3A4 (1.00) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| Adiphenine SCHEMBL27972992 | 0.97 | LMNA (0.94) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| Butetamate SCHEMBL1643343 | 0.84 | KDM4E (0.84) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26100 | 0.81 | CYP3A4 (0.70) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| Butetamate SCHEMBL8721011 | 0.81 | KDM4E (0.78) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL9588277 | 0.80 | KDM4E (0.78) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL9588408 | 0.79 | KDM4E (0.76) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL28529361 | 0.79 | LMNA (0.64) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL17715387 | 0.78 | KMT2A (0.69) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL2859577 | 0.78 | LMNA (0.63) | LMNACYP1A2CYP2D6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12613968-B2 | Systems and methods for communication of data with isolated environments | PARRY LABS, LLC (US) | 2026-04-28 | — | — | US | claimed |
| WO-2025087695-A1 | METHOD FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES | ASCEND ADVANCED THERAPIES LTD (GB) | 2025-05-01 | — | — | WO | claimed |
| US-20230420110-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-12-28 | — | — | US | claimed |
| EP-4247259-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | Indiana University Research and Technology Corporation (US) | 2023-09-27 | — | — | EP | claimed |
| US-11608532-B2 | Precision medicine for treating and preventing suicidality | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-03-21 | — | — | US | claimed |
| WO-2022109165-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-05-27 | — | — | WO | claimed |
| US-10991449-B2 | Predicting suicidality using a combined genomic and clinical risk assessment | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-04-27 | — | — | US | claimed |
| EP-3802881-A1 | METHODS FOR ASSESSMENT AND EARLY DETECTION OF STRESS, SELECTING AND MONITORING TREATMENT, AND NEW USE FOR DRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-04-14 | — | — | EP | claimed |
| US-20200318188-A1 | PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-08 | — | — | US | claimed |
| US-20200312425-A1 | PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT | UNIV INDIANA RES & TECH CORP (US) | 2020-10-01 | — | — | US | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| CN-1450883-A | Transdermal delivery system for alkaloids of aconitum species | XEL HERBACEUTICALS (US) | 2003-10-22 | — | — | CN | claimed |
| US-20020068754-A1 | Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects | OLNEY JOHN W (US) | 2002-06-06 | — | — | US | claimed |
| WO-2001089448-A2 | COMBINATION OF ADRENERGIC AGONIST AND NMDA ANTAGONIST FOR RELIEVING CHRONIC PAIN WITHOUT ADVERSE SIDE EFFECTS | OLNEY JOHN W (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001035883-A1 | TRANSDERMAL DELIVERY SYSTEM FOR ALKALOIDS OF ACONITUM SPECIES | XEL HERBACEUTICALS (US) | 2001-05-25 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | claimed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12613968-B2 | Systems and methods for communication of data with isolated environments | INTS6, EXOSC5, DBN1 | LMNA 3867/4885CYP1A2 2500/4885CYP2D6 498/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | LMNA 891/4885CYP1A2 1571/4885CYP2D6 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.